These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 32553611)
61. [Systemic sclerosis]. Tamborrini G; Distler M; Distler O Med Monatsschr Pharm; 2008 May; 31(5):162-70; quiz 171-2. PubMed ID: 18552072 [TBL] [Abstract][Full Text] [Related]
62. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Koenig M; Joyal F; Fritzler MJ; Roussin A; Abrahamowicz M; Boire G; Goulet JR; Rich E; Grodzicky T; Raymond Y; Senécal JL Arthritis Rheum; 2008 Dec; 58(12):3902-12. PubMed ID: 19035499 [TBL] [Abstract][Full Text] [Related]
63. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Classen JF; Henrohn D; Rorsman F; Lennartsson J; Lauwerys BR; Wikström G; Rorsman C; Lenglez S; Franck-Larsson K; Tomasi JP; Kämpe O; Vanthuyne M; Houssiau FA; Demoulin JB Arthritis Rheum; 2009 Apr; 60(4):1137-44. PubMed ID: 19333949 [TBL] [Abstract][Full Text] [Related]
70. [Autoantibodies in systemic sclerosis]. Żebryk P; Puszczewicz M Postepy Hig Med Dosw (Online); 2015 May; 69():654-60. PubMed ID: 26035026 [TBL] [Abstract][Full Text] [Related]
71. Systemic sclerosis: current views of its pathogenesis. Derk CT; Jimenez SA Autoimmun Rev; 2003 Jun; 2(4):181-91. PubMed ID: 12848944 [TBL] [Abstract][Full Text] [Related]
72. New developments in the pathogenesis of systemic sclerosis. Sakkas LI Autoimmunity; 2005 Mar; 38(2):113-6. PubMed ID: 16040330 [TBL] [Abstract][Full Text] [Related]
73. Clinical characteristics of sarcoidosis patients with systemic sclerosis-specific autoantibody: Possible involvement of thymus and activation-regulated chemokine and a review of the published works. Ueda-Hayakawa I; Nguyen CTH; Kishimoto I; Ly NTM; Okamoto H J Dermatol; 2019 Jul; 46(7):577-583. PubMed ID: 31131913 [TBL] [Abstract][Full Text] [Related]
75. Scleroderma - new aspects in pathogenesis and treatment. Balbir-Gurman A; Braun-Moscovici Y Best Pract Res Clin Rheumatol; 2012 Feb; 26(1):13-24. PubMed ID: 22424190 [TBL] [Abstract][Full Text] [Related]
76. A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies. Cavazzana I; Fredi M; Taraborelli M; Quinzanini M; Tincani A; Franceschini F Clin Exp Rheumatol; 2013; 31(2 Suppl 76):118-21. PubMed ID: 23910615 [TBL] [Abstract][Full Text] [Related]
77. Is scleroderma an autoantibody mediated disease? Arnett FC Curr Opin Rheumatol; 2006 Nov; 18(6):579-81. PubMed ID: 17053501 [TBL] [Abstract][Full Text] [Related]
78. [Systemic sclerosis--clinical course and treatment possibilities]. Szymańska E; Maj M; Rudnicka L Przegl Lek; 2005; 62(12):1538-41. PubMed ID: 16786791 [TBL] [Abstract][Full Text] [Related]
79. B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets. Yoshizaki A J Dermatol; 2016 Jan; 43(1):39-45. PubMed ID: 26782005 [TBL] [Abstract][Full Text] [Related]
80. The heart and pulmonary arterial hypertension in systemic sclerosis. Vandecasteele EH; De Pauw M; Brusselle G; Decuman S; Piette Y; De Keyser F; Smith V Acta Clin Belg; 2016 Feb; 71(1):1-18. PubMed ID: 27075793 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]